Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal Aflibercept for Persistent Central Serous Chorioretinopathy
NCT01710332Phase 2Completed
- Sponsor
- Wills Eye Hospital
- Start
- Oct 2012
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of aflibercept in Central Serous Chorioretinopathy (CSCR), sponsored by Wills Eye Hospital. Started Oct 2012; status: completed.
02
Drugs
aflibercept
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NCT01710332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01710332.